Kereos, Inc. develops targeted molecular imaging agents and therapeutics designed to detect and treat cancer and cardiovascular disease earlier and more specifically than previously possible. The specificity and unique capabilities of Kereos' molecular imaging agents enable earlier and more definitive diagnosis of disease. Similarly, Kereos' targeted therapeutics seek out definitive disease biomarkers and carry powerful payloads of proven chemotherapeutics, making them potentially more effective and less toxic in treating disease.